Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Evaluation of Frailty and Functional Capacity in End-Stage Liver Disease
Authors not listed
Hacettepe University · 2022
Abstract
Development of fibrosis plays a main role in the pathophysiology of liver diseases. The rate of progression in fibrogenesis varies according to the type of underlying liver disease and varies with the environment and host-related factors. End-stage liver diseases are characterized by systemic vascular resistance and decreased arterial blood pressure, increased heart rate and cardiac output . Disruption of regulation of neurogenic, humoral and vascular functions is effective in these cardiovascular changes. In end-stage liver diseases, glycogen storage and corruption of glyconeogenesis cause muscle protein and fat to be used for energy, resulting in weight loss and muscle weakness. According to the latest data of the Republic of Turkey Ministry of Health in Turkey in 2223 patients are waiting for liver transplantation. Acute and chronic liver disease and infectious complications lead to an increase in the number of hospitalizations and prolonged hospital stay and severely affect the functional status and mortality. In recent years, more attention has been paid to complications from chronic diseases, including malnutrition, sarcopenia, poor functional capacity, and frailty. There are few studies in the literature examining functional capacity and physical frailty in end-stage liver disease. The aim of this study was to investigate the relationship between functional capacity and frailty in end-stage liver disease.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-28 MST
Cite this
APA
Anonymous. (2022). Evaluation of Frailty and Functional Capacity in End-Stage Liver Disease. <em>Hacettepe University</em>. https://clinicaltrials.gov/study/NCT04220723
Vancouver
Anonymous. Evaluation of Frailty and Functional Capacity in End-Stage Liver Disease. Hacettepe University. 2022.
BibTeX
@misc{anon2022Evalua,
title = {Evaluation of Frailty and Functional Capacity in End-Stage Liver Disease},
author = {Anonymous},
journal = {Hacettepe University},
year = {2022},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Shanghai Zhongshan Hospital 2021
Open access · US-GOV
Zhongshan Hospital, Fudan University
Frontiers in Endocrinology 2024
Open access · CC-BY
Type 2 diabetes mellitus related sarcopenia: a type of muscle loss distinct from sarcopenia and disuse muscle atrophy
Physiology International 2023
Open access · OA
Dasatinib and quercetin increase testosterone and sperm concentration in mice
Shanghai Jiao Tong University School of Medicine 2020
Open access · US-GOV
The Relationship Between Sarcopenia and Cardiovascular Disease in Chronic Kidney Disease Stage 3 or Higher and the Risk Involved.
International Journal of Molecular Sciences 2022
Open access · CC-BY
Aging of Liver in Its Different Diseases
Clinical Cancer Bulletin 2024
Open access · CC-BY